# Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

> **NCT02097719** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 100 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost 0.01%
- **DRUG:** travoprost 0.004%
- **DRUG:** timolol 0.5%
- **DRUG:** hypromellose 0.3%

## Key facts

- **NCT ID:** NCT02097719
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097719, "Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02097719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*